Ann: VivaGel BV sales and distribution agreement MENA region, page-10

Hahaha @antibotter forever the spin merchant.

The facts are that this product has been sold in the Middle East (under the previous agreement) since 2018. By the pitiful gross (world) revenue received into Starpharma coffers during this period, I would speculate that Middle East (ME) contribution was insignificant.

But apparently now it’s a big deal. Good one AB. lol.

Even 5 years ago Starpharma managed to eek a tiny $1.3m upfront licence fee out of the deal which included the ME region.

Not this time though. A big fat ZERO.

P.S. BV prevalence amongst Middle Eastern women is significantly lower than those in the US if you dig down into Starpharma’s own data.